enGene Therapeutics Inc. 8-K

What Happened

• enGene Therapeutics Inc. filed a Current Report on Form 8-K on July 17, 2026 (Item 7.01) to disclose an updated corporate presentation. The presentation is furnished as Exhibit 99.1 to the filing. The report was signed by Ronald H. W. Cooper, Chief Executive Officer and President.

Key Details

• Filing date: July 17, 2026.
• Purpose: Regulation FD disclosure of an updated corporate presentation (Exhibit 99.1).
• Signatory: /s/ Ronald H. W. Cooper, CEO and President.
• The 8-K does not report earnings, revenue, executive changes, mergers, or other financial results.

Why It Matters

• An updated corporate presentation can contain refreshed information on the company’s strategy, pipeline, milestones or investor messaging; investors should review Exhibit 99.1 to see any substantive updates.
• Because this was filed as a Regulation FD disclosure, the company is publicly furnishing the material to ensure fair public access. If you follow enGene for investment purposes, check the exhibit and watch for any subsequent press releases or SEC filings that provide detailed financial or operational updates.